Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to 0.02%.

  • Ligand Pharmaceuticals' Return on Invested Capital rose 300.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.05% for FY2024, which is 300.0% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Return on Invested Capital stood at 0.02%, which was up 300.0% from 0.04% recorded in Q2 2025.
  • Ligand Pharmaceuticals' Return on Invested Capital's 5-year high stood at 0.14% during Q2 2021, with a 5-year trough of 0.06% in Q1 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' median Return on Invested Capital value was 0.01% (recorded in 2023), while the average stood at 0.03%.
  • The largest annual percentage gain for Ligand Pharmaceuticals' Return on Invested Capital in the last 5 years was 1500bps (2021), contrasted with its biggest fall of -2300bps (2021).
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Return on Invested Capital stood at 0.13% in 2021, then tumbled by -100bps to 0.0% in 2022, then skyrocketed by 2598bps to 0.01% in 2023, then skyrocketed by 194bps to 0.04% in 2024, then plummeted by -65bps to 0.02% in 2025.
  • Its Return on Invested Capital stands at 0.02% for Q3 2025, versus 0.04% for Q2 2025 and 0.06% for Q1 2025.